Research programme: protein modulator therapies - Origami Therapeutics
Latest Information Update: 06 Oct 2022
At a glance
- Originator Origami Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Protein conformation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease